- Home
- VIGL vs ICCM Comparison
VIGL vs ICCM Comparison
Compare VIGL & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ICCM
- Stock Information
- Founded
- VIGL 2020
- ICCM 2006
- Country
- VIGL United States
- ICCM Israel
- Employees
- VIGL N/A
- ICCM N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- VIGL Health Care
- ICCM
- Exchange
- VIGL Nasdaq
- ICCM Nasdaq
- Market Cap
- VIGL 89.3M
- ICCM 75.8M
- IPO Year
- VIGL 2022
- ICCM N/A
- Fundamental
- Price
- VIGL $3.03
- ICCM $1.41
- Analyst Decision
- VIGL Strong Buy
- ICCM Strong Buy
- Analyst Count
- VIGL 5
- ICCM 2
- Target Price
- VIGL $21.00
- ICCM $2.70
- AVG Volume (30 Days)
- VIGL 642.5K
- ICCM 379.2K
- Earning Date
- VIGL 03-25-2025
- ICCM 04-02-2025
- Dividend Yield
- VIGL N/A
- ICCM N/A
- EPS Growth
- VIGL N/A
- ICCM N/A
- EPS
- VIGL N/A
- ICCM N/A
- Revenue
- VIGL N/A
- ICCM $3,671,000.00
- Revenue This Year
- VIGL N/A
- ICCM $10.03
- Revenue Next Year
- VIGL N/A
- ICCM $62.68
- P/E Ratio
- VIGL N/A
- ICCM N/A
- Revenue Growth
- VIGL N/A
- ICCM 26.02
- 52 Week Low
- VIGL $1.49
- ICCM $0.48
- 52 Week High
- VIGL $6.06
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- VIGL 77.87
- ICCM 60.09
- Support Level
- VIGL $2.71
- ICCM $1.22
- Resistance Level
- VIGL $2.95
- ICCM $1.66
- Average True Range (ATR)
- VIGL 0.21
- ICCM 0.09
- MACD
- VIGL 0.03
- ICCM 0.01
- Stochastic Oscillator
- VIGL 86.18
- ICCM 43.18
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.